查看購物車
  • Simplified Chinese
  • English
歐洲疫苗佐劑市場預測至 2030 年 - 區域分析 - 按佐劑類別（礦物鹽佐劑、乳液佐劑、脂質體佐劑等）和類型（人用疫苗佐劑和獸用疫苗佐劑）
市場調查報告書
商品編碼
1666310

歐洲疫苗佐劑市場預測至 2030 年 - 區域分析 - 按佐劑類別（礦物鹽佐劑、乳液佐劑、脂質體佐劑等）和類型（人用疫苗佐劑和獸用疫苗佐劑）

Europe Vaccine Adjuvants Market Forecast to 2030 - Regional Analysis - by Adjuvant Class (Mineral Salt Adjuvant, Emulsion Adjuvant, Liposome Adjuvant, and Others) and Type (Human Vaccine Adjuvant and Veterinary Vaccine Adjuvant)
出版日期: | 出版商: The Insight Partners | 英文 93 Pages | 訂單完成後即時交付

價格

2022年歐洲疫苗佐劑市值為7.405億美元，預計到2030年將達到20.5105億美元；預計 2022 年至 2030 年的複合年成長率為 13.6%。

獸用疫苗佐劑的批准推動歐洲疫苗佐劑市場

為動物接種常見疾病疫苗仍然是全球範圍內防止動物養殖中傳染病造成經濟和其他損失最成功的方法。隨著製造商越來越注重開發更有效、更穩定的疫苗，獸用疫苗佐劑的監管批准正在增加。 Montanide 是已知的獸用疫苗佐劑之一。 Montanide 佐劑系列以三大核心技術為基礎—乳液、微乳液和聚合物。因此，獸用疫苗佐劑核准數量的激增加速了疫苗佐劑整體市場的成長。

歐洲疫苗佐劑市場概況

歐洲疫苗佐劑市場細分為德國、英國、法國、義大利、西班牙和歐洲其他地區。德國有幾家頂級疫苗製造商。 2022年12月，贏創推出了名為PhytoSquene的植物性角鯊烯，以提高疫苗有效性。它是一種非動物衍生物，適用於疫苗和其他藥物應用。 PhytoSquene 是已知的第一個引入市場的從莧菜油中提取的角鯊烯，用作非腸道用藥的佐劑。贏創的這項最新創新旨在為市場提供永續的、非動物衍生解決方案。 2021年，贏創推出醫藥級植物源膽固醇「PhytoChol」。

歐洲疫苗佐劑市場收入及 2030 年預測（百萬美元）

歐洲疫苗佐劑市場區隔

歐洲疫苗佐劑市場分為佐劑類別、類型和國家。

依佐劑類別，歐洲疫苗佐劑市場分為礦物鹽佐劑、乳液佐劑、脂質體佐劑等。 2022 年，礦物鹽佐劑佔據歐洲疫苗佐劑市場的最大佔有率。

根據類型，歐洲疫苗佐劑市場分為人用疫苗佐劑和獸用疫苗佐劑。 2022 年，人類疫苗佐劑部分佔據了歐洲疫苗佐劑市場的較大佔有率。

依國家分類，歐洲疫苗佐劑市場分為德國、英國、法國、義大利、西班牙和歐洲其他地區。 2022 年，德國佔據歐洲疫苗佐劑市場佔有率的主導地位。

Croda International Plc； CSL有限公司； Dynavax Technologies Corp；葛蘭素史克公司； InvivoGen SAS； Novavax Inc.； Phibro 動物健康公司；塞皮克 SA；和 SPI Pharma Inc 是歐洲疫苗佐劑市場的一些領先公司。

目錄

第 1 章：簡介

第 2 章：執行摘要

  • 關鍵見解

第3章：研究方法

  • 覆蓋範圍
  • 二次研究
  • 初步研究

第 4 章：歐洲疫苗佐劑市場 - 主要市場動態

  • 歐洲疫苗佐劑市場 - 主要市場動態
  • 市場促進因素
    • 傳染病爆發和疫情數量不斷增加
    • 獸用疫苗佐劑的核准
  • 市場限制
    • 產品召回和不良影響
  • 市場機會
    • 生物技術和免疫學的進展
  • 未來趨勢
    • 技術進步
  • 促進因素和限制因素的影響：

第 5 章：疫苗佐劑市場 - 歐洲市場分析

  • 歐洲疫苗佐劑市場 - 收入和 2030 年預測
  • 歐洲疫苗佐劑市場預測與分析

第 6 章：歐洲疫苗佐劑市場分析 - 按佐劑類別

  • 概述
  • 礦物鹽佐劑
  • 乳化助劑
  • 脂質體佐劑
  • 其他

第 7 章：歐洲疫苗佐劑市場分析 - 按類型

  • 人類疫苗佐劑
  • 獸用疫苗佐劑

第 8 章：歐洲疫苗佐劑市場 - 國家分析

  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 其餘

第9章：產業格局

  • 概述
  • 全球疫苗佐劑市場的成長策略
  • 有機發展
    • 概述
  • 無機發展
    • 概述

第10章：公司簡介

  • SPI Pharma Inc
  • GSK Plc
  • CSL Ltd
  • Seppic SA
  • Dynavax Technologies Corp
  • InvivoGen SAS
  • Croda International Plc
  • Novavax Inc
  • Phibro Animal Health Corp

第 11 章：附錄

Product Code: BMIRE00031104

The Europe vaccine adjuvants market was valued at US$ 740.50 million in 2022 and is expected to reach US$ 2,051.05 million by 2030; it is estimated to register a CAGR of 13.6% from 2022 to 2030 .

Approvals of Veterinary Vaccine Adjuvants Drive Europe Vaccine Adjuvants Market

Vaccinating animals against common diseases remains the most successful method worldwide to prevent financial and other losses from infectious diseases in animal farming. Regulatory approvals for veterinary vaccine adjuvants are increasing, with manufacturers' growing focus on developing vaccines with greater efficacy and stability. Montanide is one of the known veterinary vaccine adjuvants. The Montanide adjuvant range is based on three core technologies-emulsions, micro-emulsions, and polymers. Therefore, an upsurge in adjuvant approvals for veterinary vaccines accelerates the overall market growth of vaccine adjuvants.

Europe Vaccine Adjuvants Market Overview

The Europe vaccine adjuvant market has been segmented into Germany, UK, France, Italy, Spain, and the Rest of Europe. A few top vaccine manufacturers have a presence in Germany. In December 2022, Evonik launched a plant-based squalene named PhytoSquene to improve vaccine efficacy. It is a non-animal derivative suitable for vaccines and other pharmaceutical applications. PhytoSquene is the first known amaranth oil-derived squalene introduced in the market for adjuvants in drugs indicated for parenteral usage. This latest innovation of Evonik is meant to provide the market with sustainable, non-animal derivative solutions. In 2021, Evonik launched the pharma-grade and plant-derived cholesterol "PhytoChol".

Europe Vaccine Adjuvants Market Revenue and Forecast to 2030 (US$ Million)

Europe Vaccine Adjuvants Market Segmentation

The Europe vaccine adjuvants market is categorized into adjuvant class, type, and country.

Based on adjuvant class, the Europe vaccine adjuvants market is segmented into mineral salt adjuvant, emulsion adjuvant, liposome adjuvant, and others. The mineral salt adjuvant segment held the largest share of the Europe vaccine adjuvants market share in 2022.

By type, the Europe vaccine adjuvants market is bifurcated into human vaccine adjuvant and veterinary vaccine adjuvant. The human vaccine adjuvant segment held a larger share of Europe vaccine adjuvants market in 2022.

By country, the Europe vaccine adjuvants market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. Germany dominated the Europe vaccine adjuvants market share in 2022.

Croda International Plc; CSL Ltd; Dynavax Technologies Corp; GSK Plc; InvivoGen SAS; Novavax Inc.; Phibro Animal Health Corp; Seppic SA; and SPI Pharma Inc are some of the leading companies operating in the Europe vaccine adjuvants market.

Table Of Contents

1. Introduction

  • 1.1 The Insight Partners Research Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights

3. Research Methodology

  • 3.1 Coverage
  • 3.2 Secondary Research
  • 3.3 Primary Research

4. Europe Vaccine Adjuvants Market - Key Market Dynamics

  • 4.1 Europe Vaccine Adjuvants Market - Key Market Dynamics
  • 4.2 Market Drivers
    • 4.2.1 Rising Number of Infectious Disease Outbreaks and Pandemic
    • 4.2.2 Approvals of Veterinary Vaccine Adjuvants
  • 4.3 Market Restraints
    • 4.3.1 Product Recalls and Adverse Effects
  • 4.4 Market Opportunities
    • 4.4.1 Advancements in Biotechnology and Immunology
  • 4.5 Future Trends
    • 4.5.1 Technological Advancements
  • 4.6 Impact of Drivers and Restraints:

5. Vaccine Adjuvants Market -Europe Market Analysis

  • 5.1 Europe Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • 5.2 Europe Vaccine Adjuvants Market Forecast and Analysis

6. Europe Vaccine Adjuvants Market Analysis - by Adjuvant Class

  • 6.1 Overview
  • 6.2 Mineral Salt Adjuvant
    • 6.2.1 Overview
    • 6.2.2 Mineral Salt Adjuvant: Europe Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • 6.3 Emulsion Adjuvant
    • 6.3.1 Overview
    • 6.3.2 Emulsion Adjuvant: Europe Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • 6.4 Liposome Adjuvant
    • 6.4.1 Overview
    • 6.4.2 Liposome Adjuvant: Europe Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • 6.5 Others
    • 6.5.1 Overview
    • 6.5.2 Others: Europe Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)

7. Europe Vaccine Adjuvants Market Analysis - by Type

  • 7.1 Human Vaccine Adjuvant
    • 7.1.1 Overview
    • 7.1.2 Human Vaccine Adjuvant: Europe Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.2 Veterinary Vaccine Adjuvant
    • 7.2.1 Overview
    • 7.2.2 Veterinary Vaccine Adjuvant: Europe Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)

8. Europe Vaccine Adjuvants Market -Country Analysis

  • 8.1 Europe
    • 8.1.1 Europe Vaccine Adjuvants Market
      • 8.1.1.1 Germany: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 8.1.1.1.1 Overview
        • 8.1.1.1.2 Germany: Glucose Monitoring Devices Market - Revenue and Forecast to 2030 (US$ Million)
        • 8.1.1.1.3 Germany: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
        • 8.1.1.1.4 Germany: Vaccine Adjuvants Market Breakdown, by Type
      • 8.1.1.2 United Kingdom: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 8.1.1.2.1 Overview
        • 8.1.1.2.2 United Kingdom: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 8.1.1.2.3 United Kingdom: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
        • 8.1.1.2.4 United Kingdom: Vaccine Adjuvants Market Breakdown, by Type
      • 8.1.1.3 France: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 8.1.1.3.1 Overview
        • 8.1.1.3.2 France: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 8.1.1.3.3 France: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
        • 8.1.1.3.4 France: Vaccine Adjuvants Market Breakdown, by Type
      • 8.1.1.4 Italy: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 8.1.1.4.1 Overview
        • 8.1.1.4.2 Italy: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 8.1.1.4.3 Italy: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
        • 8.1.1.4.4 Italy: Vaccine Adjuvants Market Breakdown, by Type
      • 8.1.1.5 Spain: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 8.1.1.5.1 Overview
        • 8.1.1.5.2 Spain: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 8.1.1.5.3 Spain: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
        • 8.1.1.5.4 Spain: Vaccine Adjuvants Market Breakdown, by Type
      • 8.1.1.6 Rest of Europe Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 8.1.1.6.1 Overview
        • 8.1.1.6.2 Rest of Europe Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 8.1.1.6.3 Rest of Europe Vaccine Adjuvants Market Breakdown, by Adjuvant Class
        • 8.1.1.6.4 Rest of Europe Vaccine Adjuvants Market Breakdown, by Type

9. Industry Landscape

  • 9.1 Overview
  • 9.2 Growth Strategies in the Global Vaccine Adjuvants Market
  • 9.3 Organic Developments
    • 9.3.1 Overview
  • 9.4 Inorganic Developments
    • 9.4.1 Overview

10. Company Profiles

  • 10.1 SPI Pharma Inc
    • 10.1.1 Key Facts
    • 10.1.2 Business Description
    • 10.1.3 Products and Services
    • 10.1.4 Financial Overview
    • 10.1.5 SWOT Analysis
    • 10.1.6 Key Developments
  • 10.2 GSK Plc
    • 10.2.1 Key Facts
    • 10.2.2 Business Description
    • 10.2.3 Products and Services
    • 10.2.4 Financial Overview
    • 10.2.5 SWOT Analysis
    • 10.2.6 Key Developments
  • 10.3 CSL Ltd
    • 10.3.1 Key Facts
    • 10.3.2 Business Description
    • 10.3.3 Products and Services
    • 10.3.4 Financial Overview
    • 10.3.5 SWOT Analysis
    • 10.3.6 Key Developments
  • 10.4 Seppic SA
    • 10.4.1 Key Facts
    • 10.4.2 Business Description
    • 10.4.3 Products and Services
    • 10.4.4 Financial Overview
    • 10.4.5 SWOT Analysis
    • 10.4.6 Key Developments
  • 10.5 Dynavax Technologies Corp
    • 10.5.1 Key Facts
    • 10.5.2 Business Description
    • 10.5.3 Products and Services
    • 10.5.4 Financial Overview
    • 10.5.5 SWOT Analysis
    • 10.5.6 Key Developments
  • 10.6 InvivoGen SAS
    • 10.6.1 Key Facts
    • 10.6.2 Business Description
    • 10.6.3 Products and Services
    • 10.6.4 Financial Overview
    • 10.6.5 SWOT Analysis
    • 10.6.6 Key Developments
  • 10.7 Croda International Plc
    • 10.7.1 Key Facts
    • 10.7.2 Business Description
    • 10.7.3 Products and Services
    • 10.7.4 Financial Overview
    • 10.7.5 SWOT Analysis
    • 10.7.6 Key Developments
  • 10.8 Novavax Inc
    • 10.8.1 Key Facts
    • 10.8.2 Business Description
    • 10.8.3 Products and Services
    • 10.8.4 Financial Overview
    • 10.8.5 SWOT Analysis
    • 10.8.6 Key Developments
  • 10.9 Phibro Animal Health Corp
    • 10.9.1 Key Facts
    • 10.9.2 Business Description
    • 10.9.3 Products and Services
    • 10.9.4 Financial Overview
    • 10.9.5 SWOT Analysis
    • 10.9.6 Key Developments

11. Appendix

  • 11.1 About The Insight Partners

List Of Tables

  • Table 1. Europe Vaccine Adjuvants Market Segmentation
  • Table 2. Europe Vaccine Adjuvants Market Revenue and Forecasts To 2030 (US$ Million)
  • Table 3. Germany: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Adjuvant Class
  • Table 4. Germany: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 5. United Kingdom: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Adjuvant Class
  • Table 6. United Kingdom: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 7. France: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Adjuvant Class
  • Table 8. France: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 9. Italy: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Adjuvant Class
  • Table 10. Italy: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 11. Spain: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Adjuvant Class
  • Table 12. Spain: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 13. Rest of Europe Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Adjuvant Class
  • Table 14. Rest of Europe Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 15. Organic Developments Done by Companies
  • Table 16. Inorganic Developments Done by Companies

List Of Figures

  • Figure 1. Europe Vaccine Adjuvants Market Segmentation, by Country
  • Figure 2. Impact Analysis of Drivers and Restraints
  • Figure 3. Europe Vaccine Adjuvants Market Revenue (US$ Million), 2022-2030
  • Figure 4. Europe Vaccine Adjuvants Market Share (%) - by Adjuvant Class (2022 and 2030)
  • Figure 5. Mineral Salt Adjuvant: Europe Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 6. Emulsion Adjuvant: Europe Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 7. Liposome Adjuvant: Europe Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 8. Others: Europe Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 9. Europe Vaccine Adjuvants Market Share (%) - by Type (2022 and 2030)
  • Figure 10. Human Vaccine Adjuvant: Europe Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 11. Veterinary Vaccine Adjuvant: Europe Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 12. Europe Vaccine Adjuvants Market - Revenue by Key Countries Revenue 2022 (US$ Million)
  • Figure 13. Europe Vaccine Adjuvants Market (2022 and 2030)
  • Figure 14. Germany: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 15. United Kingdom: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 16. France: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 17. Italy: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 18. Spain: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 19. Rest of Europe Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 20. Growth Strategies in the Vaccine Adjuvants Market